Head of Translational Research
Melissa Ashlock, M.D.,
Melissa Ashlock (formerly Rosenfeld) M.D. currently serves as the Head of Translational Research at the Genomics Institute of the Novartis Research Foundation (GNF), where she is responsible for leading cross-disciplinary efforts to advance the Institute’s pre-clinical drug discovery portfolio across multiple disease areas. Prior to joining GNF in 2016, Dr. Ashlock was Senior Vice President of Translational Medicine and Therapeutics at aTyr Pharma. While at aTyr Pharma, she also served as lead physician in clinical development, where she championed the development of Resolaris™ and its investigation for the treatment of rare genetic muscle diseases. Dr. Ashlock also held executive leadership positions at the Cystic Fibrosis Foundation (CFF), where she was responsible for several small molecule CFTR modulator programs between the CFF and companies within the pharmaceutical industry. Her scientific and translational activities helped set the stage for the successful development of two drugs approved for cystic fibrosis, Kalydeco® and Orkambi®. Prior to this CFF work, Dr. Ashlock led the development of novel strategies for gene transfer and gene therapy at the NIH, in the vector development core of the NHGRI and the pulmonary branch of the NHLBI. Dr. Ashlock received her M.D. from Cornell University Medical College and her B.S. in biochemistry from Purdue University. She received a distinguished alumnus award from the School of Agriculture at Purdue in 1998.